Advertisement

Topics

Exon-Intron, Inc. Company Profile

15:36 EDT 24th September 2017 | BioPortfolio

Exon-Intron, Inc. is a biotechnology education firm. This year we celebrate our 18th anniversary and the continuation of our long tradition as a provider of expert technical training to scientists of virtually every level of sophistication. By placing great emphasis on hands-on, laboratory-intensive training, our workshops provide the researcher with the necessary skills and insight to plan and perform cutting-edge research, and to interpret the resulting data. These programs are comprehensive and provide the participant with enough knowledge to be conversant in the language of biotechnology and to teach these methods to students in all areas of science.

Location

P.O. Box 395
Loganville
Pennsylvania
17342
United States of America

Contact

Phone: 717-428-3780
Fax: 717-771-4062
Email: workshop@DNAtech.com


News Articles [31 Associated News Articles listed on BioPortfolio]

Sarepta, BioMarin Settle Exon Skipping Patent Dispute

Sarepta Therapeutics will license global exclusive rights to BioMarin Pharmaceutical’s patent estate for the marketed Duchenne muscular dystrophy (DMD) treatment Exondys 51™ (eteplirsen) and all f...

Sarepta, BioMarin Settle Exon-Skipping Patent Dispute

Sarepta Therapeutics will license global exclusive rights to BioMarin Pharmaceutical’s patent estate for the marketed Duchenne muscular dystrophy (DMD) treatment Exondys 51™ (eteplirsen) and all f...

Sarepta, BioMarin settle patent litigation over DMD exon-skipping drugs

Sarepta Therapeutics and BioMarin Pharmaceutical have settled a global patent litigation relating to the use of the former’s Exondys 51 and all future exon-skipping products for the treatment of Duc...

Sarepta Opens Research and Manufacturing Center in Andover, MA

Sarepta Therapeutics today is formally opening its Research and Manufacturing Center in Andover, MA, with plans to double its workforce there over the next year to year-and-a-half—less than a year a...

BioMarin, Sarepta resolve exon-skipping patent litigation; Sarepta keeps global DMD rights for $100mm

BioMarin Pharmaceutical Inc. and Sarepta Therapeutics Inc. resolved ongoing litigation surrounding patent rights (owned by BioMarin under a previous license from Leiden University) related to Sarepta'...

Usher syndrome candidate receives orphan drug designation

The FDA and the European Medicines Agency have granted orphan drug designation to QRX-421, an investigational drug for Usher syndrome, according to a press release from ProQR Therapeutics.The investig...

Sarepta reports Phase I/II data for exon 53 DMD candidate

Sarepta gains on Phase I/II data for exon 53 DMD candidate

Drugs and Medications [11 Associated Drugs and Medications listed on BioPortfolio]

Ribavirin [Aurobindo Pharma Limited]

These highlights do not include all the information needed to use ribavirin safely and effectively. See full prescribing information for ribavirin capsules. Ribavirin Capsules Initial U.S. Approval: ...

Ribavirin [Cadila Healthcare Limited]

These highlights do not include all the information needed to use ribavirin capsules safely and effectively. See full prescribing information for ribavirin capsules. Initial U.S. Approval: 1998

Ribavirin [Zydus Pharmaceuticals (USA) Inc.]

These highlights do not include all the information needed to use ribavirin capsules safely and effectively. See full prescribing information for ribavirin capsules. Initial U.S. Approval: 1998

Ribavirin [Sandoz Inc]

These highlights do not include all the information needed to use Ribavirin safely and effectively. See full prescribing information for Ribavirin.Ribavirin Capsules Initial U.S. Approval: 1998

Ribavirin [American Health Packaging]

These highlights do not include all the information needed to use Ribavirin safely and effectively. See full prescribing information for Ribavirin.Ribavirin Capsules Initial U.S. Approval: 1998

PubMed Articles [288 Associated PubMed Articles listed on BioPortfolio]

HFE gene polymorphism defined by sequence based typing of the Brazilian population and a standardized nomenclature for HFE allele sequences.

The HFE molecule controls iron uptake from gut, and defects in the molecule have been associated with iron overload, particularly in hereditary hemochromatosis. The HFE gene including both coding and ...

Widespread intra-dependencies in the removal of introns from human transcripts.

Research into the problem of splice site selection has followed a reductionist approach focused on how individual splice sites are recognized. Early applications of information theory uncovered an inc...

Cornelia de lange syndrome with thyroid agenesis of an indonesian patient.

Cornelia de Lange syndrome (CdLs), which is also called Brachmann de Lange syndrome, is a congenital disorder characterized by distinctive facial features, prenatal and postnatal growth deficiency, fe...

A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy.

Spinal muscular atrophy (SMA) is a neuromuscular disease caused by reduced expression of survival of motor neuron (SMN), a protein expressed in humans by two paralogous genes, SMN1 and SMN2. These gen...

RNA Trans-Splicing Targeting Endogenous β-Globin Pre-Messenger RNA in Human Erythroid Cells.

Sickle cell disease results from a point mutation in exon 1 of the β-globin gene (total 3 exons). Replacing sickle β-globin exon 1 (and exon 2) with a normal sequence by trans-splicing is a potentia...

Clinical Trials [98 Associated Clinical Trials listed on BioPortfolio]

Phase III PEG-Intron in HIV-infected Patients (Study P00738)

This is a randomized, double-blind, multicenter trial testing 2 doses of PEG-Intron, 1.0mcg/kg/week and 3.0mcg/kg/week in heavily treatment-experienced HIV-infected patients compared to pl...

Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children

The purpose of this study is to see if PEG-Intron is safe and tolerated when given to children, to see how much gets into the blood and how long it stays in the blood, and to see how well ...

Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron

This is an open-label, single-arm, multicenter Phase II safety and efficacy study of combination therapy with pembrolizumab and PEG-Intron (Peginterferon alpha-2b) in patients with advance...

Peg-Intron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (Study P04498)(COMPLETED)

This is an open label, randomized, comparative, multi-center study. Subjects will be screened within 2 weeks prior to study entry to establish eligibility. Subjects who meet all the sele...

Study of Patients With Chronic Hepatitis C Infected With HCV LVL 1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793 Part 2)

To determine the relapse rate at 24 weeks follow up in HCV LVL G1 patients treated for 24 weeks with Peg Intron and Rebetol who are HCV-RNA negative at treatment week 4 and week 24. To det...

Companies [8 Associated Companies listed on BioPortfolio]

Exon-Intron, Inc.

Exon-Intron, Inc. is a biotechnology education firm. This year we celebrate our 18th anniversary and the continuation of our long tradition as a provider of expert technical training to scientists of ...

INTRON BIO TECHNOLOGY

NIL

Receptor BioLogix

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of prot...

Receptor BioLogix, Inc.

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of prot...

Prosensa

Prosensa is an innovative Dutch biopharmaceutical company focused on the discovery, development and commercialization of RNA modulating therapeutics correcting gene expression in ...

More Information about "Exon-Intron, Inc." on BioPortfolio

We have published hundreds of Exon-Intron, Inc. news stories on BioPortfolio along with dozens of Exon-Intron, Inc. Clinical Trials and PubMed Articles about Exon-Intron, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Exon-Intron, Inc. Companies in our database. You can also find out about relevant Exon-Intron, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...


Corporate Database Quicklinks



Searches Linking to this Company Record